European Commission approves CAPRELSA® (vandetanib) for patients with advanced medullary thyroid cancer
21 February 2012 | By AstraZeneca
Marketing authorisation for CAPRELSA® (vandetanib) granted...
List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
21 February 2012 | By AstraZeneca
Marketing authorisation for CAPRELSA® (vandetanib) granted...
2 February 2012 | By AstraZeneca
AstraZeneca has announced new restructuring initiatives designed to improve productivity and strengthen the company’s capabilities...
19 January 2012 | By AstraZeneca
The FDA has issued a complete response letter regarding dapagliflozin...
11 January 2012 | By AstraZeneca
AstraZeneca has entered into a three-year collaboration agreement with IMS Health...
9 January 2012 | By AstraZeneca
The info was out of date planning information...
20 December 2011 | By AstraZeneca
With associated impairment charges, company confirms full year financial target...
15 December 2011 | By AstraZeneca
AstraZeneca announced that the German assessment body, the Federal Joint Committee (G-BA), has issued its final decision regarding the medical benefit of BRILIQUE (ticagrelor)...
8 December 2011 | By AstraZeneca
AstraZeneca to acquire Guangdong BeiKang Pharmaceutical Company Ltd...
8 December 2011 | By AstraZeneca
Company will reduce its US sales force by approximately 1,150 leadership positions and sales representatives...
5 December 2011 | By AstraZeneca
A wide range of compounds will be made available FOC to UK medical researchers...
29 November 2011 | By AstraZeneca
The European Commission has granted marketing authorisation for KOMBOGLYZE™...
28 November 2011 | By Bristol-Myers Squibb Company
The European Commission has approved ONGLYZA® (saxagliptin)...
28 November 2011 | By AstraZeneca
MedImmune Ventures closes investment in Australian company, NeuProtect Pty Ltd...
18 November 2011 | By AstraZeneca
CAPRELSA receives a positive opinion...
15 November 2011 | By AstraZeneca
Data presented at this year’s AHA reinforces the established efficacy profile of CRESTOR...